
Please try another search
Investing.com -- Abbott Laboratories (NYSE:ABT) said Friday that it could restart its Sturgis, Michigan plant within two weeks, pending FDA approval.
In February, Abbott recalled three baby-formula products after reports of infant illness, including two infants who died.
Abbott is one of the biggest baby formula suppliers in the U.S. and the recall has fueled an industry-wide baby formula shortage.
According to a report from Bloomberg, during a routine visit to Abbott’s Sturgis, Michigan, manufacturing facility in September, FDA inspectors "determined that employees may have transferred contaminants including deadly cronobacter from surfaces to baby formula."
However, Abbott has denied its formula is to blame, with the company telling Bloomberg that "There is no evidence to link our formulas to these infant illnesses.”
In a statement today, Abbott said it is working to address an FDA list of observations so it can restart the Sturgis, Michigan facility.
"Subject to FDA approval, we could restart the site within two weeks," Abbott stated.
By Victoria Waldersee BERLIN (Reuters) - BMW is exploring new investments in solar, geothermal and hydrogen energy to lower its dependence on natural gas, the carmaker's...
By Gina Lee Investing.com – Asia Pacific stocks were mostly down on Monday morning, with investors continuing to assess the economic growth outlook for the world’s largest...
By Oliver Gray Investing.com - The S&P/ASX 200 added 26.1 points or 0.4% to 7,171.7 after the first hour of Monday’s trade, extending last week’s gain of 1% in its first session...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.